The ARMC9 Knockout HAP1 Polyclonal Cells are a ready-to-use CRISPR/Cas9-edited polyclonal population with targeted disruption of the ARMC9 gene in the HAP1 human near-haploid cell line. This product provides a heterogeneous ensemble of knockout genotypes, enabling robust loss-of-function studies without single-cell clone isolation. The polyclonal format maintains genetic diversity while ensuring efficient ARMC9 disruption, suitable for functional genomics, drug screening, and pathway interrogation.
The HAP1 cell line originates from the KBM-7 chronic myeloid leukemia (CML) cell line and retains a near-haploid karyotype (one copy of most chromosomes). This haploid genetic configuration facilitates straightforward CRISPR/Cas9 gene knockout by requiring disruption of only a single allele, resulting in loss of gene function. HAP1 cells are extensively characterized for genetic screens, offering a simplified genetic background ideal for elucidating gene function in signaling, protein trafficking, and disease mechanisms.
ARMC9 encodes an armadillo repeat-containing protein that localizes to the ciliary transition zone, a critical gatekeeper for ciliary protein composition. ARMC9 is transcriptionally regulated by RFX3 and FOXJ1, master regulators of ciliogenesis, and functions downstream of hedgehog ligands SHH, IHH, and DHH. Within the transition zone, ARMC9 interacts with core scaffolding proteins including CEP290, RPGRIP1L, NPHP1, INPP5E, and TECT2. This complex ensures proper trafficking of hedgehog signaling components??such as the transmembrane receptor SMO, negative regulator PTCH1, and transcriptional effector GLI1??as well as intraflagellar transport proteins IFT88, BBS4, and kinesin KIF7. Disruption of ARMC9 impairs the ciliary entry of these factors, sequestering GLI activators and attenuating GLI-mediated transcription of hedgehog target genes. Consequently, ARMC9 loss uncouples hedgehog signaling from its ciliary platform, mimicking ciliopathy conditions.
In the HAP1 near-haploid context, ARMC9 knockout provides a clean genetic model to dissect ciliary signaling without confounding diploid allelic interactions. This is particularly advantageous for studying the hedgehog pathway, where subtle changes in protein stoichiometry can drastically alter outcome. The cells recapitulate molecular hallmarks of Joubert syndrome type 30 and other ciliopathies, including defective ciliogenesis, aberrant GLI activity, and disrupted cell cycle progression. The haploid background enhances the power of genetic and pharmacological screens aimed at identifying suppressors or activators of ciliary signaling, offering a potent platform for drug target validation and mechanistic studies of transition zone function.
These polyclonal knockout cells are suited for a broad range of experimental applications, including ciliopathy modeling, functional genomics screens, and drug target validation. Researchers can employ techniques such as quantitative Western blotting to assess ARMC9 and pathway protein levels, RT-qPCR to measure GLI1 transcript changes, immunofluorescence to visualize cilia (using ARL13B and acetylated tubulin markers), and hedgehog-responsive luciferase reporter assays to quantify pathway activity. Co-immunoprecipitation experiments enable analysis of the ARMC9 interactome, while RNA-sequencing provides transcriptome-wide insights. For further information, customization, or bulk orders, please contact Ascent Research.
